乳e學院Logo
  • 線上學習
  • 致謝
  • 常見問題
  • 回官網
  • 登入
  • 複習課程
    2022年乳癌治療新知年度回顧(線上) The year in review of breast cancer treatment
    精選課程
    外科手術
    內科用藥
    專業 4.0
    修課人數:49
    2022年乳癌治療新知年度回顧(線上) The year in review of breast cancer treatment

    (請注意 此堂課為課後複習,無積分登錄)

     

    贊助廠商
    more
  • 全新上架
    Escaping negativity by adding platinum to TNBC neoadjuvant therapy
    精選課程
    內科用藥
    專業 1.0
    修課人數:73
    Escaping negativity by adding platinum to TNBC neoadjuvant therapy

    Adding platinum to neoadjuvant chemotherapy has been proved to increase the pCR rate in TNBC patients and the accompanying adverse effect is tolerable and manageable although the benefit of overall survival has not been well-established.

    This lecture aims to present the efficacy and safety of various neoadjuvant regimens for patients diagnosed with early stage or locally advanced triple-negative breast cancer (TNBC).

    贊助廠商
    more
  • 最新上架
    Revisiting Docetaxel Schedule in Breast Cancer
    精選課程
    內科用藥
    專業 2.0
    修課人數:84
    Revisiting Docetaxel Schedule in Breast Cancer

    Administration of docetaxel in a weekly schedule may offer similar efficacy, with a more favorable toxicity profile, compared to a three-weekly schedule in patients with breast cancer. 
    This presentation will revisit Docetaxel schedule in early breast cancer & metastatic breast cancer. 

    贊助廠商
    more
  • Systemic Chemotherapy after CDK 4/6 inhibitors in Luminal-type Advanced Breast cancer
    精選課程
    內科用藥
    專業 1.0
    修課人數:137
    Systemic Chemotherapy after CDK 4/6 inhibitors in Luminal-type Advanced Breast cancer

    對於 HR+/HER2- MBC 的病人,不管是內生性或經過內分泌藥物治療後,所產生的賀爾蒙抗性是無法避免的,如何選擇下一階段治療的化療藥物,這將是當務之急… 

    贊助廠商
    more
  • Highlights, ESMO 2022
    精選課程
    外科手術
    內科用藥
    專業 2.0
    修課人數:159
    Highlights, ESMO 2022

    2022年11月10日(四)19:00-20:30,台灣乳房醫學會將於乳e學院線上直播,陳守棟理事長將為大家分享ESMO 2022的課程會議亮點!
    歡迎您踴躍加入我的課程報名!

    贊助廠商
    more
  • A Careful Reassessment of Anthracyclines Use in HER2 Negative Breast Cancer
    精選課程
    內科用藥
    專業 1.0
    修課人數:112
    A Careful Reassessment of Anthracyclines Use in HER2 Negative Breast Cancer

    De-escalating anthracycline is gaining popularity for breast cancer patients.  This lecture aims to present the non-inferiority of an anthracycline-free regimen to the standard anthracycline- based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer and identify patients who are suitable for anthracycline-free regimen.

    贊助廠商 賽諾菲股份有限公司
    more
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
載入更多
乳e學院Logo 台灣乳房醫學會
  • 02-25239118
  • bcst@ms46.hinet.net
  • 10457台北市中山區吉林路24號6樓
All Copyright Reserved by 2021 TBCS